Reviva Pharmaceuticals Holdings (RVPH) Accumulated Expenses (2021 - 2026)

Reviva Pharmaceuticals Holdings has reported Accumulated Expenses for 6 years, with the latest figure at $408519.0 in Q1 2026.

• Quarterly Accumulated Expenses fell 26.64% year-over-year to $408519.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $408519.0 (down 26.64% YoY) and the FY2025 annual result came in at $485899.0, down 23.55% from the prior year.
• Accumulated Expenses fell to $408519.0 in Q1 2026 per RVPH's latest filing, from $485899.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $12.0 million in Q4 2023 and troughed at $408519.0 in Q1 2026.
• A 5-year average of $3.8 million and a median of $2.2 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses soared 513.4% in 2023, then tumbled 94.69% in 2024.
• Over 5 years, Accumulated Expenses stood at $5.6 million in 2022, then soared by 114.52% to $12.0 million in 2023, then sank by 94.69% to $635587.0 in 2024, then retreated by 23.55% to $485899.0 in 2025, then fell by 15.93% to $408519.0 in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $408519.0, $485899.0, and $784956.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.